Radiotherapy promotes cuproptosis and synergizes with cuproptosis inducers to overcome tumor radioresistance
Menée à l'aide de lignées cellulaires, d'échantillons de tumeurs de l'oesophage et de xénogreffes sur des modèles murins, cette étude démontre un lien entre radiothérapie et cuproptose puis met en évidence l'intérêt de combiner radiothérapie et ionophores cupriques pour lever efficacement la radiorésistance des cellules cancéreuses
Cuproptosis is a recently identified form of copper-dependent cell death. Here, we reveal that radiotherapy (RT) induces cuproptosis in cancer cells, independent of apoptosis and ferroptosis, and depletes lipoylated proteins and iron-sulfur (Fe-S) cluster proteins?both hallmarks of cuproptosis?in patient tumors. Mechanistically, RT elevates mitochondrial copper levels by upregulating copper transporter 1 (CTR1) and depleting mitochondrial glutathione, a copper chelator, thereby triggering cuproptosis. Integrated analyses of RNA sequencing (RNA-seq) from radioresistant esophageal cancer cells and single-cell RNA-seq from esophageal tumors of patients unresponsive to RT link radioresistance to the downregulation of BTB and CNC homology 1 (BACH1). This downregulation de-represses the expression of copper-sequestering metallothionein (MT) 1E/X, thereby mitigating cuproptosis and contributing to radioresistance. Copper ionophore treatment sensitizes radioresistant cancer cells and cell line- and patient-derived xenografts to RT by potentiating cuproptosis. Our findings unveil a link between RT and cuproptosis and inform a therapeutic strategy to overcome tumor radioresistance by targeting cuproptosis.
Cancer Cell , article en libre accès 2024